CLDXCelldex Therapeutics, Inc.
$29.89+21% 1Y
$29.89
$22.5852 weeks$44.88
CLDX in its own filings
CLDX's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
454
Events found in the filings · across 1,295 filings · the record starts in 1995
- Hard flags
- 3
Hard flags
- Most recent filing
- Sep 22, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 6, 1995
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountanthistorical
- 2008-06-09
- Late periodic report2 occurrences
- 2008-05-09
- Delisting notice / listing-rule failure6 occurrences
- 2018-11-27
- SEC comment-letter activity31 occurrences
- 2020-06-12
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 22, 2026On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU)Other event · Form 8-K
- Aug 6, 2026Celldex Reports Second Quarter Financial Results and Provides Corporate Update.Earnings release · press release
- Jul 15, 2026On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.Director or officer change · Form 8-K
- Jun 26, 2026On June 25, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Celldex Therapeutics, Inc. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) (i) increasing the number of shares available …Director or officer change · Form 8-K
- May 7, 2026Celldex Reports First Quarter Financial Results and Provides Corporate Update.Earnings release · press release
- Apr 2, 2026On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of …Material agreement entered · Form 8-K
- Feb 25, 2026Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Nov 10, 2025Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks